株探米国株
英語
エドガーで原本を確認する
0000719135false00007191352024-08-082024-08-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

August 8, 2024

Date of Report (date of earliest event reported)
apyx8klogo.jpg
APYX MEDICAL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
001-31885
11-2644611
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
5115 Ulmerton Road, Clearwater, Florida 33760
(Address of principal executive offices, zip code)
(727) 384-2323
Registrant's telephone number, including area code
_____________________________________________________________
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A common stock APYX Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o



Item 5.07. Submission of Matters to a Vote of Security Holders.

On August 8, 2024, the following proposals were submitted to the stockholders of Apyx Medical Corporation (the “Company”) at its annual meeting of stockholders: (1) the election of eight (8) directors; and (2) the ratification of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024. The proposals are described in more detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on June 25, 2024.

The following are the final voting results for each proposal.

Proposal 1: The Company’s stockholders elected each of the following eight (8) directors to serve on the Board of Directors of the Company until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, by the following vote:
Name Number of Votes
Cast in Favor
Number of Votes
Cast Against
Number of Votes
Abstained
Broker Non-Votes
Stavros G. Vizirgianakis 14,111,703 92,624 5,246 7,211,012
Charles D. Goodwin 13,178,641 867,864 163,068 7,211,012
Michael Geraghty 13,457,404 584,101 168,068 7,211,012
Lawrence J. Waldman 13,459,116 582,389 168,068 7,211,012
John Andres 13,506,328 535,177 168,068 7,211,012
Craig Swandal 13,650,856 390,625 168,092 7,211,012
Minnie Baylor-Henry 13,506,826 535,574 167,173 7,211,012
Wendy Levine 13,604,393 435,548 169,632 7,211,012

Proposal 2:
The Company’s stockholders ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024 by the following vote:
Number of Votes
Cast in Favor
Number of Votes
Cast Against
Number of Votes
Abstained
Broker Non-Votes
20,781,403 595,809 43,373




SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 12, 2024 Apyx Medical Corporation
By: /s/ Matthew Hill
Matthew Hill
Chief Financial Officer, Secretary and Treasurer